BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schuster Bruce C, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med 2019;16:e1002873. [PMID: 31504034 DOI: 10.1371/journal.pmed.1002873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP; on behalf of the MACUSTAR Consortium. Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions. Ophthalmologica 2021;244:387-95. [PMID: 33285549 DOI: 10.1159/000513591] [Reference Citation Analysis]
2 Doleman B, Mathiesen O, Jakobsen JC, Sutton AJ, Freeman S, Lund JN, Williams JP. Methodologies for systematic reviews with meta-analysis of randomised clinical trials in pain, anaesthesia, and perioperative medicine. Br J Anaesth 2021;126:903-11. [PMID: 33558052 DOI: 10.1016/j.bja.2021.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ciani O, Grigore B, Taylor RS. Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence. Health Econ 2022. [PMID: 35608044 DOI: 10.1002/hec.4524] [Reference Citation Analysis]
4 Sanna L, Todea A. Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials? Respir Med Res 2022;81:100893. [PMID: 35523041 DOI: 10.1016/j.resmer.2022.100893] [Reference Citation Analysis]
5 Geybels M, Wolthers BO, Kreiner FF, Rasmussen S, Bauer R. Surrogate endpoint evaluation using data from one large global randomized controlled trial. BMC Med Inform Decis Mak 2021;21:164. [PMID: 34016120 DOI: 10.1186/s12911-021-01516-8] [Reference Citation Analysis]
6 Saesen R, Lacombe D, Huys I. Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer. Eur J Cancer 2021;151:221-32. [PMID: 34023561 DOI: 10.1016/j.ejca.2021.04.012] [Reference Citation Analysis]
7 Duncan HF, Nagendrababu V, El-Karim IA, Dummer PMH. Outcome measures to assess the effectiveness of endodontic treatment for pulpitis and apical periodontitis for use in the development of European Society of Endodontology (ESE) S3 level clinical practice guidelines: a protocol. Int Endod J 2021;54:646-54. [PMID: 33630330 DOI: 10.1111/iej.13501] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dawoud D, Naci H, Ciani O, Bujkiewicz S. Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ 2021;374:n2191. [PMID: 34526320 DOI: 10.1136/bmj.n2191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mahlich J, Bartol A, Dheban S. Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Econ Rev 2021;11:4. [PMID: 33454837 DOI: 10.1186/s13561-021-00302-6] [Reference Citation Analysis]
10 Vitry A, Mintzes B. "Drugs to avoid" to improve quality use of medicines: how is Australia faring? J Pharm Policy Pract 2021;14:60. [PMID: 34256874 DOI: 10.1186/s40545-021-00346-3] [Reference Citation Analysis]
11 Grössmann N, Wolf S, Rothschedl E, Wild C. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'. ESMO Open 2021;6:100166. [PMID: 34087744 DOI: 10.1016/j.esmoop.2021.100166] [Reference Citation Analysis]
12 Ortiz Y, Fareli CJ, Gallegos V, Hernández E. Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico. Value Health Reg Issues 2021;26:75-88. [PMID: 34130223 DOI: 10.1016/j.vhri.2021.04.002] [Reference Citation Analysis]
13 Theissen JL, Zahn P, Theissen U, Brehler R. [Allergic and pseudo-allergic reactions in anesthesia. II: Symptoms, diagnosis, therapy, prevention]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1995;30:71-76. [PMID: 7772660 DOI: 10.1111/1468-0009.12476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
14 Hoang T, Kim J. Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers (Basel) 2020;12:E2663. [PMID: 32961943 DOI: 10.3390/cancers12092663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Saesen R, Lejeune S, Quaglio G, Lacombe D, Huys I. Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. Front Pharmacol 2020;11:43. [PMID: 32116718 DOI: 10.3389/fphar.2020.00043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, Kouhsari E, Goudarzi M, Heidary M. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Front Microbiol 2021;12:717045. [PMID: 34690963 DOI: 10.3389/fmicb.2021.717045] [Reference Citation Analysis]